Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain
Sponsor: Novartis Pharmaceuticals
Summary
This study aims to characterize the patient profiles and the clinical experience of iptacopan treatment in adult patients with C3G treated through an early access program (EAP) in Spain.
Official title: Clinical Experience With Iptacopan in Adult Patients With Complement 3 Glomerulopathy (C3G): A Multicenter, Observational, Retrospective Study of Patients Treated Through an Early Access Program in Spain
Key Details
Gender
All
Age Range
18 Years - 100 Years
Study Type
OBSERVATIONAL
Enrollment
35
Start Date
2026-09-22
Completion Date
2026-12-15
Last Updated
2026-11-17
Healthy Volunteers
No
Conditions
Locations (5)
Novartis Investigative Site
Las Palmas de Gran C, Las Palmas, Spain
Novartis Investigative Site
Valencia, Valencia, Spain
Novartis Investigative Site
Córdoba, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Madrid, Spain